Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D Shore

Showing results (481-490 of 590) with videos related to

Pageof 59
Sort By:
European Urology|July 13, 2016
Subsequent Chemotherapy and Treatment Patterns After Abiraterone Acetate in Patients with Metastatic Castration-resistant Prostate Cancer: Post Hoc Analysis of COU-AA-302Johann S de Bono, Matthew R Smith, Fred Saad, et al.
The Prostate|February 17, 2015
Safety of enzalutamide in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel: expanded access in North AmericaAnthony M Joshua, Neal D Shore, Fred Saad, et al.
European Urology|March 19, 2017
Clinical Outcomes from Androgen Signaling-directed Therapy after Treatment with Abiraterone Acetate and Prednisone in Patients with Metastatic Castration-resistant Prostate Cancer: Post Hoc Analysis of COU-AA-302Matthew R Smith, Fred Saad, Dana E Rathkopf, et al.
European Urology Oncology|June 12, 2024
Expert Consensus Recommendations on the Management of Treatment-emergent Adverse Events Among Men with Prostate Cancer Taking Poly-ADP Ribose Polymerase Inhibitor + Novel Hormonal Therapy Combination TherapyNeal D Shore, Michael S Broder, Pedro C Barata, et al.
Bladder Cancer (Amsterdam, Netherlands)|July 12, 2024
Reduced Dose Intravesical Bacillus Calmette-Guérin: Why It Might Not MatterAshish M Kamat, Niyati Lobo, Seth P Lerner, et al.
Future Oncology (London, England)|January 8, 2024
CREST: phase III study of sasanlimab and Bacillus Calmette-Guérin for patients with Bacillus Calmette-Guérin-naïve high-risk non-muscle-invasive bladder cancerGary D Steinberg, Neal D Shore, Joan Palou Redorta, et al.
European Urology|May 13, 2023
The Efficacy of Enzalutamide plus Androgen Deprivation Therapy in Oligometastatic Hormone-sensitive Prostate Cancer: A Post Hoc Analysis of ARCHESAndrew J Armstrong, Taro Iguchi, Arun A Azad, et al.
NEJM Evidence|February 6, 2024
Enzalutamide and Quality of Life in Biochemically Recurrent Prostate CancerStephen J Freedland, Martin Gleave, Ugo De Giorgi, et al.
The New England Journal of Medicine|June 1, 2026
PARP and Androgen-Signaling Inhibition plus ADT in Metastatic Prostate CancerNeeraj Agarwal, Nobuaki Matsubara, Arun A Azad, et al.
Cancer Chemotherapy and Pharmacology|March 23, 2021
Niraparib with androgen receptor-axis-targeted therapy in patients with metastatic castration-resistant prostate cancer: safety and pharmacokinetic results from a phase 1b study (BEDIVERE)Fred Saad, Kim N Chi, Neal D Shore, et al.
Pageof 59

Showing results (481-490 of 590) with videos related to

Sort By:
Pageof 59
European Urology|July 13, 2016
Subsequent Chemotherapy and Treatment Patterns After Abiraterone Acetate in Patients with Metastatic Castration-resistant Prostate Cancer: Post Hoc Analysis of COU-AA-302Johann S de Bono, Matthew R Smith, Fred Saad, et al.
The Prostate|February 17, 2015
Safety of enzalutamide in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel: expanded access in North AmericaAnthony M Joshua, Neal D Shore, Fred Saad, et al.
European Urology|March 19, 2017
Clinical Outcomes from Androgen Signaling-directed Therapy after Treatment with Abiraterone Acetate and Prednisone in Patients with Metastatic Castration-resistant Prostate Cancer: Post Hoc Analysis of COU-AA-302Matthew R Smith, Fred Saad, Dana E Rathkopf, et al.
European Urology Oncology|June 12, 2024
Expert Consensus Recommendations on the Management of Treatment-emergent Adverse Events Among Men with Prostate Cancer Taking Poly-ADP Ribose Polymerase Inhibitor + Novel Hormonal Therapy Combination TherapyNeal D Shore, Michael S Broder, Pedro C Barata, et al.
Bladder Cancer (Amsterdam, Netherlands)|July 12, 2024
Reduced Dose Intravesical Bacillus Calmette-Guérin: Why It Might Not MatterAshish M Kamat, Niyati Lobo, Seth P Lerner, et al.
Future Oncology (London, England)|January 8, 2024
CREST: phase III study of sasanlimab and Bacillus Calmette-Guérin for patients with Bacillus Calmette-Guérin-naïve high-risk non-muscle-invasive bladder cancerGary D Steinberg, Neal D Shore, Joan Palou Redorta, et al.
European Urology|May 13, 2023
The Efficacy of Enzalutamide plus Androgen Deprivation Therapy in Oligometastatic Hormone-sensitive Prostate Cancer: A Post Hoc Analysis of ARCHESAndrew J Armstrong, Taro Iguchi, Arun A Azad, et al.
NEJM Evidence|February 6, 2024
Enzalutamide and Quality of Life in Biochemically Recurrent Prostate CancerStephen J Freedland, Martin Gleave, Ugo De Giorgi, et al.
The New England Journal of Medicine|June 1, 2026
PARP and Androgen-Signaling Inhibition plus ADT in Metastatic Prostate CancerNeeraj Agarwal, Nobuaki Matsubara, Arun A Azad, et al.
Cancer Chemotherapy and Pharmacology|March 23, 2021
Niraparib with androgen receptor-axis-targeted therapy in patients with metastatic castration-resistant prostate cancer: safety and pharmacokinetic results from a phase 1b study (BEDIVERE)Fred Saad, Kim N Chi, Neal D Shore, et al.
Pageof 59